Abstract
Fifty percent of patients with the myelodysplastic syndrome, frequently following treatment by radiation or chemotherapy, have prognostically unfavorable deletions of the long arms of chromosomes 5 and 7, or trisomy 8, as have the 25% of patients with acute myeloblastic leukemia where remissions last 6–12 months, and where relapse cannot be prevented. In contrast, patients with prognostically favorable cytogenetics (translocation 15; 17 or 8; 21 or inversion 16) maintenance chemotherapy may prevent relapses. Of chronic myelocytic leukemia patients, 85% can achieve hematological remission with interferon α, and 40% a partial cytogenetic remission, which probably delays relapse.
Original language | English (US) |
---|---|
Pages (from-to) | 155-158 |
Number of pages | 4 |
Journal | Medical Oncology and Tumor Pharmacotherapy |
Volume | 8 |
Issue number | 3 |
DOIs | |
State | Published - Sep 1991 |
Keywords
- Cytogenetics
- Leukemia
- Molecular genetics
- Prevention
- Residual disease
- Treatment
ASJC Scopus subject areas
- Oncology
- Cancer Research